As part of the special issue on Pediatric Neuro-Oncology, this article will focus on 4 of the rarer tumors in this spectrum, including atypical teratoid rhabdoid tumors, embryonal tumors with multilayered rosettes, choroid plexus tumors, and pleomorphic xanthoastrocytoma. Incidence and current understanding of the molecular pathogenesis of these tumors are discussed, and avenues of therapy both current and prospective are explored.
TekautzTMFullerCEBlaneyS. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005;23:1491–1499.
2.
PackerRJBiegelJABlaneyS. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002;24:337–342.
3.
RorkeLBPackerRBiegelJ. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol. 1995;24:21–28.
4.
KubickyCDSahgalAChangELLoSS. Rare primary central nervous system tumors. Rare Tumors. 2014;6:5449.
5.
BurgerPCYuITTihanT. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998;22:1083–1092.
6.
BiegelJAZhouJYRorkeLBStenstromCWainwrightLMFogelgrenB. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999;59:74–79.
7.
RobertsCWBiegelJA. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther. 2009;8:412–416.
8.
GinnKFGajjarA. Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol. 2012;2:114.
9.
SlavcIChocholousMLeissU. Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. Cancer Med. 2014;3:91–100.
10.
ShihCSHaleGAGronewoldL. High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer. 2008;112:1345–1353.
11.
GardnerSLAsgharzadehSGreenAHornBMcCowageGFinlayJ. Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer. 2008;51:235–240.
12.
NicolaidesTTihanTHornBBiegelJPradosMBanerjeeA. High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol. 2010;98:117–123.
13.
FidaniPDe IorisMASerraA. A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience. J Neurooncol. 2009;92:177–183.
14.
Finkelstein-ShechterTGassasAMabbottD. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol. 2010;32:e182–e186.
15.
ParkESSungKWBaekHJ. Tandem high-dose chemotherapy and autologous stem cell transplantation in young children with atypical teratoid/rhabdoid tumor of the central nervous system. J Korean Med Sci. 2012;27:135–140.
16.
ChiSNZimmermanMAYaoX. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27:385–389.
17.
WeberDCAresCMalyapaR. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy. J Neurooncol. 2015;121:389–397.
18.
WetmoreCBoyettJLiS. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro Oncol. 2015;17:882–888.
19.
TsikitisMZhangZEdelmanWZagzagDKalpanaGV. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci U S A. 2005;102:12129–12134.
20.
D’CunjaJShalabyTRiveraP. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur J Cancer. 2007;43:1581–1589.
21.
EberhartCGBratDJCohenKJBurgerPC. Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol. 2000;3:346–352.
22.
AdamekDSofoworaKDCwiklinskaMHerman-SucharskaIKwiatkowskiS. Embryonal tumor with abundant neuropil and true rosettes: an autopsy case-based update and review of the literature. Childs Nerv Syst. 2013;29:849–854.
23.
DunhamCSugoETobiasVWillsEPerryA. Embryonal tumor with abundant neuropil and true rosettes (ETANTR): report of a case with prominent neurocytic differentiation. J Neurooncol. 2007;84:91–98.
24.
NobusawaSYokooHHiratoJ. Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol. 2012;22:689–697.
25.
SpenceTSin-ChanPPicardD. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014;128:291–303.
26.
KorshunovASturmDRyzhovaM. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014;128:279–289.
27.
GessiMGiangasperoFLauriolaL. Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol. 2009;33:211–217.
28.
KleinmanCLGergesNPapillon-CavanaghS. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat Genet. 2014;46:39–44.
29.
SafaeeMOhMCBlochO. Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis. Neuro Oncol. 2013;15:255–267.
30.
RickertCHWiestlerODPaulusW. Chromosomal imbalances in choroid plexus tumors. Am J Pathol. 2002;160:1105–1113.
31.
ZakyWDhallGKhatuaS. Choroid plexus carcinoma in children: the Head Start experience. Pediatr Blood Cancer. 2015;62:784–789.
32.
WredeBLiuPWolffJE. Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol. 2007;85:345–351.
33.
IdaCMRodriguezFJBurgerPC. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol. 2015;25:575–586.
34.
KoelscheCSahmFWohrerA. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol. 2014;24:221–229.
35.
BettegowdaCAgrawalNJiaoY. Exomic sequencing of four rare central nervous system tumor types. Oncotarget. 2013;4:572–583.
36.
ChappeCPadovaniLScavardaD. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol. 2013;23:574–583.
37.
Dias-SantagataDLamQVernovskyK. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011;6:e17948.
38.
GrauEBalaguerJCaneteA. Subtelomeric analysis of pediatric astrocytoma: subchromosomal instability is a distinctive feature of pleomorphic xanthoastrocytoma. J Neurooncol. 2009;93:175–182.
39.
SawyerJRRolosonGJChadduckWMBoopFA. Cytogenetic findings in a pleomorphic xanthoastrocytoma. Cancer Genet Cytogenet. 1991;55:225–230.
40.
YinXLHuiABLiongECDingMChangARNgHK. Genetic imbalances in pleomorphic xanthoastrocytoma detected by comparative genomic hybridization and literature review. Cancer Genet Cytogenet. 2002;132:14–19.
41.
GalloPCecchiPCLocatelliF. Pleomorphic xanthoastrocytoma: long-term results of surgical treatment and analysis of prognostic factors. Br J Neurosurg. 2013;27:759–764.
